Plasticell receives EU funding to advance neurodegenerative disease research
Th company's CombiCult combinatorial cell culture technology will be used to generate high fidelity, progenitor and terminally differentiated neuronal and glial cell subtypes for incorporation into next-generation models.
Plasticell, a developer of stem cell technologies and regenerative medicines, has announced that the Advanced Stem Cell Training Network (ASCTN), a European research consortium in which the company is a partner organisation, has successfully bid for over €3,700,000 in funding from the European Union to create and exploit advanced cellular models of neurological disorders – notably Parkinson's, Huntington's and Demyelination disease - which are caused by acute or progressive loss of cells in the brain.
“Neurodegeneration is a hallmark of many incurable diseases that are fast becoming major global health problems as the world’s elderly population continues to increase”, commented Dr Yen Choo, founder and Executive Chairman of Plasticell. “Discovering effective treatments for these conditions will require a deeper understanding of disease mechanisms, as well as more effective drug screening strategies, both of which will benefit from better cellular models of neurodegeneration.”
Alongside Plasticell, the research Network also comprises the Karolinska Institute, San Raffaele Hospital, Cardiff University, University of Barcelona, Autonomous University of Madrid, Institute for Bioengineering of Catalonia, Technical University of Dresden and Poietis SA. ASCTN is funded by the European Union Horizon 2020 Programme (H2020-MSCA-ITN-2018) under the Marie Skłodowska-Curie Initial Training Network and Grant Agreement No. 813851.
The different participating laboratories specialise in human stem cell manipulation, combinatorial cell culture, directed neuronal and glial differentiation, microfluidics and single cell analysis, advanced imaging, brain-on-chip and 3D tissue engineering. Moreover, other key specialisms include cerebral organoids, ex vivo gene expression, direct cellular reprograming, mouse genetic modification, animal models of neurological disease, scaffold implantation and stem cell transplants into the brain.
Plasticell’s CombiCult combinatorial cell culture technology will specifically be used to generate high fidelity, progenitor and terminally differentiated neuronal and glial cell subtypes for incorporation into next-generation models. Of particular interest is a brain-on-chip model to study interactions between patient iPSC-derived striatal medium spiny neurons (MSN) and dopaminergic neurons.
“We are delighted to be part of this exciting European consortium of scientists and engineers who will apply diverse technologies to produce patient-specific human neural models in test tubes, microchips or model organisms,” Dr Choo added.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance